MEDX Oncology East


Session 4: Redefining Care for BRCA-Associated Cancers

Thursday, September 7     1:45pm – 2:45pm

Description

Advances in molecular genetics have refined the management implications of BRCA-associated cancers, as BRCA mutations represent a biomarker predictive of sensitivity to treatment with PARP inhibitors. As women with germline BRCA1 and BRCA2 mutations are at an increased risk for developing high-grade serous ovarian cancer, there are implications for mutation testing and pharmaceutical interventions in the community setting. Many options have been tested in these populations, including chemotherapy-based regimens, PARP inhibitors, and targeted agents under investigation. Molecular and genetic advances, such as novel PARP inhibitors, are altering the treatment landscape for recurrent ovarian cancer.

Appropriate evidence-based care and demonstration of high-quality care are consistent with clinical guidelines and will directly affect reimbursement incentives within the new payment models.

Session Outline

Faculty will discuss 2-3 patient stories to highlight the factors that impact treatment decisions in BRCA-related ovarian and breast cancer. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • Risk assessment, genetic counseling and genetic testing for BRCA-related cancers
  • Clinical guidelines and current challenges in testing
  • Recent clinical trial updates on PARP inhibitors and platinum chemotherapy
  • Promising novel agents in clinical development

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 1.0 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hours (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon